Physician profile
Wayne S Margolis
NPI 1609871334
$19,355.66
in general payments reported to CMS, 2019-2025
34 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,391 · 2020: $2,957 · 2021: $1,785 · 2022: $1,375 · 2023: $1,317 · 2024: $1,357 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,649 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,649.23 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $8,465.30 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,538.15 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $1,252.24 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Ingevity Mri |
| E.R. Squibb & Sons, L.L.C. | $1,162.19 | 2019-2024 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $959.36 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $862.42 | 2021-2025 | Verquvo, Capvaxive, Lagevrio |
| Lilly USA, LLC | $581.34 | 2021-2025 | Zepbound, Mounjaro |
| Amarin Pharma, INC. | $510.48 | 2019-2022 | |
| Amgen INC. | $479.62 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $454.18 | 2019-2024 | Xarelto |
| Abbott Laboratories | $274.95 | 2020-2025 | Aveir, Mitraclip, Diamondback Peripheral |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $266.49 | 2019-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $228.45 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $200.00 | 2023 | |
| Esperion Therapeutics, INC. | $171.76 | 2020-2023 | Nexletol |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $153.79 | 2023-2024 | Inpefa |
| Astrazeneca Pharmaceuticals Lp | $133.88 | 2019-2025 | Farxiga |
| Baxter Healthcare | $98.52 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Inari Medical, INC. | $71.97 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Kestra Medical Technology Services, INC. | $66.63 | 2025 | Assure Wcd |
| Cleerly, INC. | $63.09 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Actelion Pharmaceuticals US, INC. | $54.03 | 2024 | Opsumit, Uptravi |
| Abiomed | $43.24 | 2024 | Impella |
| Janssen Scientific Affairs, LLC | $37.00 | 2022 | |
| Arbor Pharmaceuticals, INC. | $29.57 | 2019-2021 | |
| Gilead Sciences, INC. | $28.81 | 2019 | |
| Stryker Corporation | $24.08 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Scpharmaceuticals INC. | $22.92 | 2025 | |
| Masimo Corporation | $22.52 | 2024 | Set and Rainbow Set |
| Cagent Vascular INC | $22.44 | 2025 | Serrantor |
| Edwards Lifesciences Corporation | $22.42 | 2025 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $18.78 | 2022 | |
| Convatec INC. | $17.54 | 2023 | |
| Novo Nordisk INC | $17.50 | 2024 | Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Margolis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.